Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats, and horses. Its lead product candidates are the intravenous, or IV, form of Zimeta (dipyrone injection), previously known as KIND-012, for the control of pyrexia (fever) in horses and Mirataz (mirtazapine transdermal ointment), formerly known as KIND-010, for management of weight loss in cats. In addition, the Company has other product candidates, including several biologics, in various stages of development.